id	sid	tid	token	lemma	pos
dpc-688	1	1	dermatology	dermatology	NOUN
dpc-688	1	2	:	:	PUNCT
dpc-688	1	3	practical	practical	ADJ
dpc-688	1	4	and	and	CCONJ
dpc-688	1	5	conceptual	conceptual	ADJ
dpc-688	1	6	300	300	NUM
dpc-688	1	7	letter	letter	NOUN
dpc-688	1	8	|	|	ADV
dpc-688	1	9	dermatol	dermatol	ADJ
dpc-688	1	10	pract	pract	NOUN
dpc-688	1	11	concept	concept	NOUN
dpc-688	1	12	2019;9(4):11	2019;9(4):11	NUM
dpc-688	1	13	dermatology	dermatology	NOUN
dpc-688	1	14	practical	practical	ADJ
dpc-688	1	15	&	&	CCONJ
dpc-688	1	16	conceptual	conceptual	ADJ
dpc-688	1	17	introduction	introduction	NOUN
dpc-688	1	18	concomitant	concomitant	ADJ
dpc-688	1	19	cancers	cancer	NOUN
dpc-688	1	20	in	in	ADP
dpc-688	1	21	psoriasis	psoriasis	NOUN
dpc-688	1	22	patients	patient	NOUN
dpc-688	1	23	often	often	ADV
dpc-688	1	24	pose	pose	VERB
dpc-688	1	25	significant	significant	ADJ
dpc-688	1	26	limitations	limitation	NOUN
dpc-688	1	27	in	in	ADP
dpc-688	1	28	treatment	treatment	NOUN
dpc-688	1	29	decision	decision	NOUN
dpc-688	1	30	.	.	PUNCT
dpc-688	2	1	in	in	ADP
dpc-688	2	2	contrast	contrast	NOUN
dpc-688	2	3	to	to	ADP
dpc-688	2	4	the	the	DET
dpc-688	2	5	majority	majority	NOUN
dpc-688	2	6	of	of	ADP
dpc-688	2	7	the	the	DET
dpc-688	2	8	available	available	ADJ
dpc-688	2	9	systemic	systemic	ADJ
dpc-688	2	10	antipsoriatic	antipsoriatic	ADJ
dpc-688	2	11	drugs	drug	NOUN
dpc-688	2	12	,	,	PUNCT
dpc-688	2	13	apremilast	apremilast	NOUN
dpc-688	2	14	is	be	AUX
dpc-688	2	15	not	not	PART
dpc-688	2	16	contraindicated	contraindicate	VERB
dpc-688	2	17	in	in	ADP
dpc-688	2	18	case	case	NOUN
dpc-688	2	19	of	of	ADP
dpc-688	2	20	previous	previous	ADJ
dpc-688	2	21	or	or	CCONJ
dpc-688	2	22	concomitant	concomitant	ADJ
dpc-688	2	23	malignancy	malignancy	NOUN
dpc-688	2	24	[	[	X
dpc-688	2	25	1	1	NUM
dpc-688	2	26	]	]	PUNCT
dpc-688	2	27	.	.	PUNCT
dpc-688	3	1	we	we	PRON
dpc-688	3	2	report	report	VERB
dpc-688	3	3	a	a	DET
dpc-688	3	4	patient	patient	NOUN
dpc-688	3	5	with	with	ADP
dpc-688	3	6	psoriasis	psoriasis	NOUN
dpc-688	3	7	and	and	CCONJ
dpc-688	3	8	lung	lung	NOUN
dpc-688	3	9	adenocarcinoma	adenocarcinoma	NOUN
dpc-688	3	10	who	who	PRON
dpc-688	3	11	completely	completely	ADV
dpc-688	3	12	responded	respond	VERB
dpc-688	3	13	to	to	PART
dpc-688	3	14	apremilast	apremilast	VERB
dpc-688	3	15	.	.	PUNCT
dpc-688	4	1	the	the	DET
dpc-688	4	2	patient	patient	NOUN
dpc-688	4	3	provided	provide	VERB
dpc-688	4	4	written	write	VERB
dpc-688	4	5	informed	inform	VERB
dpc-688	4	6	consent	consent	NOUN
dpc-688	4	7	for	for	ADP
dpc-688	4	8	the	the	DET
dpc-688	4	9	data	datum	NOUN
dpc-688	4	10	reported	report	VERB
dpc-688	4	11	in	in	ADP
dpc-688	4	12	the	the	DET
dpc-688	4	13	current	current	ADJ
dpc-688	4	14	manuscript	manuscript	NOUN
dpc-688	4	15	.	.	PUNCT
dpc-688	5	1	case	case	NOUN
dpc-688	5	2	presentation	presentation	NOUN
dpc-688	5	3	a	a	DET
dpc-688	5	4	67	67	NUM
dpc-688	5	5	-	-	PUNCT
dpc-688	5	6	year	year	NOUN
dpc-688	5	7	-	-	PUNCT
dpc-688	5	8	old	old	ADJ
dpc-688	5	9	woman	woman	NOUN
dpc-688	5	10	visited	visit	VERB
dpc-688	5	11	the	the	DET
dpc-688	5	12	outpatient	outpatient	NOUN
dpc-688	5	13	unit	unit	NOUN
dpc-688	5	14	for	for	ADP
dpc-688	5	15	an	an	DET
dpc-688	5	16	exacerbation	exacerbation	NOUN
dpc-688	5	17	of	of	ADP
dpc-688	5	18	psoriasis	psoriasis	NOUN
dpc-688	5	19	(	(	PUNCT
dpc-688	5	20	psoriasis	psoriasis	NOUN
dpc-688	5	21	area	area	NOUN
dpc-688	5	22	and	and	CCONJ
dpc-688	5	23	severity	severity	NOUN
dpc-688	5	24	index	index	NOUN
dpc-688	5	25	[	[	X
dpc-688	5	26	pasi	pasi	NOUN
dpc-688	5	27	]	]	X
dpc-688	5	28	score	score	NOUN
dpc-688	5	29	at	at	ADP
dpc-688	5	30	baseline	baseline	NOUN
dpc-688	5	31	visit	visit	NOUN
dpc-688	5	32	:	:	PUNCT
dpc-688	5	33	18	18	NUM
dpc-688	5	34	)	)	PUNCT
dpc-688	5	35	.	.	PUNCT
dpc-688	6	1	in	in	ADP
dpc-688	6	2	2013	2013	NUM
dpc-688	6	3	she	she	PRON
dpc-688	6	4	received	receive	VERB
dpc-688	6	5	a	a	DET
dpc-688	6	6	diagnosis	diagnosis	NOUN
dpc-688	6	7	of	of	ADP
dpc-688	6	8	lung	lung	NOUN
dpc-688	6	9	adenocarcinoma	adenocarcinoma	NOUN
dpc-688	6	10	,	,	PUNCT
dpc-688	6	11	stage	stage	NOUN
dpc-688	6	12	iiib	iiib	NOUN
dpc-688	6	13	.	.	PUNCT
dpc-688	7	1	since	since	SCONJ
dpc-688	7	2	then	then	ADV
dpc-688	7	3	she	she	PRON
dpc-688	7	4	received	receive	VERB
dpc-688	7	5	various	various	ADJ
dpc-688	7	6	treatments	treatment	NOUN
dpc-688	7	7	,	,	PUNCT
dpc-688	7	8	including	include	VERB
dpc-688	7	9	pemetrexed	pemetrexed	PROPN
dpc-688	7	10	,	,	PUNCT
dpc-688	7	11	carboplatin	carboplatin	NOUN
dpc-688	7	12	,	,	PUNCT
dpc-688	7	13	cisplatin	cisplatin	NOUN
dpc-688	7	14	,	,	PUNCT
dpc-688	7	15	and	and	CCONJ
dpc-688	7	16	radiotherapy	radiotherapy	NOUN
dpc-688	7	17	.	.	PUNCT
dpc-688	8	1	progressive	progressive	ADJ
dpc-688	8	2	disease	disease	NOUN
dpc-688	8	3	with	with	ADP
dpc-688	8	4	liver	liver	NOUN
dpc-688	8	5	metastases	metastasis	NOUN
dpc-688	8	6	was	be	AUX
dpc-688	8	7	detected	detect	VERB
dpc-688	8	8	in	in	ADP
dpc-688	8	9	2016	2016	NUM
dpc-688	8	10	.	.	PUNCT
dpc-688	9	1	the	the	DET
dpc-688	9	2	patient	patient	NOUN
dpc-688	9	3	received	receive	VERB
dpc-688	9	4	6	6	NUM
dpc-688	9	5	courses	course	NOUN
dpc-688	9	6	of	of	ADP
dpc-688	9	7	bevacizumab	bevacizumab	NOUN
dpc-688	9	8	/	/	SYM
dpc-688	9	9	docetaxel	docetaxel	PROPN
dpc-688	9	10	/	/	SYM
dpc-688	9	11	carboplatin	carboplatin	NOUN
dpc-688	9	12	with	with	ADP
dpc-688	9	13	documented	document	VERB
dpc-688	9	14	partial	partial	ADJ
dpc-688	9	15	response	response	NOUN
dpc-688	9	16	,	,	PUNCT
dpc-688	9	17	and	and	CCONJ
dpc-688	9	18	then	then	ADV
dpc-688	9	19	nivolumab	nivolumab	NOUN
dpc-688	9	20	was	be	AUX
dpc-688	9	21	started	start	VERB
dpc-688	9	22	.	.	PUNCT
dpc-688	10	1	the	the	DET
dpc-688	10	2	treatment	treatment	NOUN
dpc-688	10	3	was	be	AUX
dpc-688	10	4	complicated	complicate	VERB
dpc-688	10	5	by	by	ADP
dpc-688	10	6	bacteremia	bacteremia	NOUN
dpc-688	10	7	.	.	PUNCT
dpc-688	11	1	antibiotics	antibiotic	NOUN
dpc-688	11	2	resulted	result	VERB
dpc-688	11	3	in	in	ADP
dpc-688	11	4	a	a	DET
dpc-688	11	5	drug	drug	NOUN
dpc-688	11	6	reaction	reaction	NOUN
dpc-688	11	7	successfully	successfully	ADV
dpc-688	11	8	managed	manage	VERB
dpc-688	11	9	with	with	ADP
dpc-688	11	10	systemic	systemic	ADJ
dpc-688	11	11	steroids	steroid	NOUN
dpc-688	11	12	.	.	PUNCT
dpc-688	12	1	systemic	systemic	ADJ
dpc-688	12	2	drugs	drug	NOUN
dpc-688	12	3	were	be	AUX
dpc-688	12	4	discontinued	discontinue	VERB
dpc-688	12	5	,	,	PUNCT
dpc-688	12	6	including	include	VERB
dpc-688	12	7	nivolumab	nivolumab	NOUN
dpc-688	12	8	,	,	PUNCT
dpc-688	12	9	despite	despite	SCONJ
dpc-688	12	10	an	an	DET
dpc-688	12	11	almost	almost	ADV
dpc-688	12	12	complete	complete	ADJ
dpc-688	12	13	resolution	resolution	NOUN
dpc-688	12	14	of	of	ADP
dpc-688	12	15	her	her	PRON
dpc-688	12	16	metastatic	metastatic	ADJ
dpc-688	12	17	disease	disease	NOUN
dpc-688	12	18	.	.	PUNCT
dpc-688	13	1	tapering	taper	VERB
dpc-688	13	2	of	of	ADP
dpc-688	13	3	steroids	steroid	NOUN
dpc-688	13	4	led	lead	VERB
dpc-688	13	5	to	to	ADP
dpc-688	13	6	exacerbation	exacerbation	NOUN
dpc-688	13	7	of	of	ADP
dpc-688	13	8	psoriasis	psoriasis	NOUN
dpc-688	13	9	.	.	PUNCT
dpc-688	14	1	clinical	clinical	ADJ
dpc-688	14	2	examination	examination	NOUN
dpc-688	14	3	revealed	reveal	VERB
dpc-688	14	4	symmetrically	symmetrically	ADV
dpc-688	14	5	distributed	distribute	VERB
dpc-688	14	6	,	,	PUNCT
dpc-688	14	7	pruritic	pruritic	NOUN
dpc-688	14	8	,	,	PUNCT
dpc-688	14	9	scaly	scaly	NOUN
dpc-688	14	10	plaques	plaque	NOUN
dpc-688	14	11	(	(	PUNCT
dpc-688	14	12	figure	figure	NOUN
dpc-688	14	13	1	1	NUM
dpc-688	14	14	,	,	PUNCT
dpc-688	14	15	a	a	PRON
dpc-688	14	16	and	and	CCONJ
dpc-688	14	17	b	b	NOUN
dpc-688	14	18	)	)	PUNCT
dpc-688	14	19	.	.	PUNCT
dpc-688	15	1	the	the	DET
dpc-688	15	2	patient	patient	NOUN
dpc-688	15	3	was	be	AUX
dpc-688	15	4	not	not	PART
dpc-688	15	5	a	a	DET
dpc-688	15	6	good	good	ADJ
dpc-688	15	7	candidate	candidate	NOUN
dpc-688	15	8	for	for	ADP
dpc-688	15	9	acitretin	acitretin	NOUN
dpc-688	15	10	.	.	PUNCT
dpc-688	16	1	after	after	ADP
dpc-688	16	2	a	a	DET
dpc-688	16	3	thorough	thorough	ADJ
dpc-688	16	4	examination	examination	NOUN
dpc-688	16	5	of	of	ADP
dpc-688	16	6	her	her	PRON
dpc-688	16	7	medical	medical	ADJ
dpc-688	16	8	profile	profile	NOUN
dpc-688	16	9	and	and	CCONJ
dpc-688	16	10	in	in	ADP
dpc-688	16	11	close	close	ADJ
dpc-688	16	12	collaboration	collaboration	NOUN
dpc-688	16	13	with	with	ADP
dpc-688	16	14	the	the	DET
dpc-688	16	15	oncologists	oncologist	NOUN
dpc-688	16	16	,	,	PUNCT
dpc-688	16	17	we	we	PRON
dpc-688	16	18	decided	decide	VERB
dpc-688	16	19	to	to	PART
dpc-688	16	20	prescribe	prescribe	VERB
dpc-688	16	21	systemic	systemic	ADJ
dpc-688	16	22	apremilast	apremilast	NOUN
dpc-688	16	23	(	(	PUNCT
dpc-688	16	24	30	30	NUM
dpc-688	16	25	mg	mg	NOUN
dpc-688	16	26	×	×	NOUN
dpc-688	16	27	2	2	NUM
dpc-688	16	28	,	,	PUNCT
dpc-688	16	29	after	after	ADP
dpc-688	16	30	dose	dose	NOUN
dpc-688	16	31	titration	titration	NOUN
dpc-688	16	32	from	from	ADP
dpc-688	16	33	day	day	NOUN
dpc-688	16	34	1	1	NUM
dpc-688	16	35	to	to	ADP
dpc-688	16	36	day	day	NOUN
dpc-688	16	37	5	5	NUM
dpc-688	16	38	)	)	PUNCT
dpc-688	16	39	.	.	PUNCT
dpc-688	17	1	the	the	DET
dpc-688	17	2	patient	patient	NOUN
dpc-688	17	3	achieved	achieve	VERB
dpc-688	17	4	pasi-75	pasi-75	PROPN
dpc-688	17	5	in	in	ADP
dpc-688	17	6	16	16	NUM
dpc-688	17	7	weeks	week	NOUN
dpc-688	17	8	(	(	PUNCT
dpc-688	17	9	pasi	pasi	VERB
dpc-688	17	10	score	score	NOUN
dpc-688	17	11	at	at	ADP
dpc-688	17	12	week	week	NOUN
dpc-688	17	13	16	16	NUM
dpc-688	17	14	:	:	SYM
dpc-688	17	15	4	4	NUM
dpc-688	17	16	)	)	PUNCT
dpc-688	17	17	(	(	PUNCT
dpc-688	17	18	figure	figure	NOUN
dpc-688	17	19	1	1	NUM
dpc-688	17	20	,	,	PUNCT
dpc-688	17	21	c	c	NOUN
dpc-688	17	22	and	and	CCONJ
dpc-688	17	23	d	d	NOUN
dpc-688	17	24	)	)	PUNCT
dpc-688	17	25	.	.	PUNCT
dpc-688	18	1	nivolumab	nivolumab	PROPN
dpc-688	18	2	was	be	AUX
dpc-688	18	3	concomitantly	concomitantly	ADV
dpc-688	18	4	reinitiated	reinitiate	VERB
dpc-688	18	5	,	,	PUNCT
dpc-688	18	6	resulting	result	VERB
dpc-688	18	7	in	in	ADP
dpc-688	18	8	a	a	DET
dpc-688	18	9	documented	document	VERB
dpc-688	18	10	response	response	NOUN
dpc-688	18	11	after	after	ADP
dpc-688	18	12	5	5	NUM
dpc-688	18	13	months	month	NOUN
dpc-688	18	14	.	.	PUNCT
dpc-688	19	1	based	base	VERB
dpc-688	19	2	on	on	ADP
dpc-688	19	3	the	the	DET
dpc-688	19	4	results	result	NOUN
dpc-688	19	5	of	of	ADP
dpc-688	19	6	imaging	imaging	NOUN
dpc-688	19	7	examinations	examination	NOUN
dpc-688	19	8	,	,	PUNCT
dpc-688	19	9	the	the	DET
dpc-688	19	10	laboratory	laboratory	NOUN
dpc-688	19	11	tests	test	NOUN
dpc-688	19	12	,	,	PUNCT
dpc-688	19	13	and	and	CCONJ
dpc-688	19	14	the	the	DET
dpc-688	19	15	overall	overall	ADJ
dpc-688	19	16	assessment	assessment	NOUN
dpc-688	19	17	by	by	ADP
dpc-688	19	18	an	an	DET
dpc-688	19	19	oncologist	oncologist	NOUN
dpc-688	19	20	,	,	PUNCT
dpc-688	19	21	there	there	PRON
dpc-688	19	22	was	be	VERB
dpc-688	19	23	no	no	DET
dpc-688	19	24	indication	indication	NOUN
dpc-688	19	25	that	that	SCONJ
dpc-688	19	26	the	the	DET
dpc-688	19	27	course	course	NOUN
dpc-688	19	28	of	of	ADP
dpc-688	19	29	the	the	DET
dpc-688	19	30	cancer	cancer	NOUN
dpc-688	19	31	or	or	CCONJ
dpc-688	19	32	the	the	DET
dpc-688	19	33	response	response	NOUN
dpc-688	19	34	to	to	ADP
dpc-688	19	35	nivolumab	nivolumab	NOUN
dpc-688	19	36	was	be	AUX
dpc-688	19	37	influenced	influence	VERB
dpc-688	19	38	by	by	ADP
dpc-688	19	39	apremilast	apremilast	ADJ
dpc-688	19	40	treatment	treatment	NOUN
dpc-688	19	41	.	.	PUNCT
dpc-688	20	1	after	after	ADP
dpc-688	20	2	12	12	NUM
dpc-688	20	3	months	month	NOUN
dpc-688	20	4	of	of	ADP
dpc-688	20	5	treatment	treatment	NOUN
dpc-688	20	6	with	with	ADP
dpc-688	20	7	apremilast	apremilast	ADJ
dpc-688	20	8	,	,	PUNCT
dpc-688	20	9	the	the	DET
dpc-688	20	10	patient	patient	NOUN
dpc-688	20	11	remains	remain	VERB
dpc-688	20	12	free	free	ADJ
dpc-688	20	13	of	of	ADP
dpc-688	20	14	psoriasis	psoriasis	NOUN
dpc-688	20	15	recurrence	recurrence	NOUN
dpc-688	20	16	.	.	PUNCT
dpc-688	21	1	psoriasis	psoriasis	NOUN
dpc-688	21	2	in	in	ADP
dpc-688	21	3	patients	patient	NOUN
dpc-688	21	4	with	with	ADP
dpc-688	21	5	active	active	ADJ
dpc-688	21	6	lung	lung	NOUN
dpc-688	21	7	cancer	cancer	NOUN
dpc-688	21	8	:	:	PUNCT
dpc-688	21	9	is	be	AUX
dpc-688	21	10	apremilast	apremilast	VERB
dpc-688	21	11	a	a	DET
dpc-688	21	12	safe	safe	ADJ
dpc-688	21	13	option	option	NOUN
dpc-688	21	14	?	?	PUNCT
dpc-688	22	1	zoe	zoe	PROPN
dpc-688	22	2	apalla1	apalla1	PROPN
dpc-688	22	3	,	,	PUNCT
dpc-688	22	4	eftychios	eftychio	VERB
dpc-688	22	5	psarakis1	psarakis1	NOUN
dpc-688	22	6	,	,	PUNCT
dpc-688	22	7	aimilios	aimilios	PROPN
dpc-688	22	8	lallas2	lallas2	PROPN
dpc-688	22	9	,	,	PUNCT
dpc-688	22	10	alexia	alexia	PROPN
dpc-688	22	11	koukouthaki1	koukouthaki1	PROPN
dpc-688	22	12	,	,	PUNCT
dpc-688	22	13	athanassios	athanassio	NOUN
dpc-688	22	14	fassas3	fassas3	PROPN
dpc-688	22	15	,	,	PUNCT
dpc-688	22	16	maria	maria	PROPN
dpc-688	22	17	smaragdi1	smaragdi1	PROPN
dpc-688	22	18	1	1	NUM
dpc-688	22	19	state	state	NOUN
dpc-688	22	20	dermatology	dermatology	NOUN
dpc-688	22	21	and	and	CCONJ
dpc-688	22	22	venereology	venereology	PROPN
dpc-688	22	23	department	department	PROPN
dpc-688	22	24	,	,	PUNCT
dpc-688	22	25	hippokration	hippokration	NOUN
dpc-688	22	26	hospital	hospital	PROPN
dpc-688	22	27	,	,	PUNCT
dpc-688	22	28	thessaloniki	thessaloniki	PROPN
dpc-688	22	29	,	,	PUNCT
dpc-688	22	30	greece	greece	PROPN
dpc-688	22	31	2	2	NUM
dpc-688	22	32	first	first	ADJ
dpc-688	22	33	dermatology	dermatology	NOUN
dpc-688	22	34	department	department	NOUN
dpc-688	22	35	,	,	PUNCT
dpc-688	22	36	aristotle	aristotle	PROPN
dpc-688	22	37	university	university	PROPN
dpc-688	22	38	of	of	ADP
dpc-688	22	39	thessaloniki	thessaloniki	PROPN
dpc-688	22	40	,	,	PUNCT
dpc-688	22	41	greece	greece	PROPN
dpc-688	22	42	3	3	NUM
dpc-688	22	43	oncology	oncology	NOUN
dpc-688	22	44	department	department	PROPN
dpc-688	22	45	,	,	PUNCT
dpc-688	22	46	st	st	PROPN
dpc-688	22	47	.	.	PROPN
dpc-688	22	48	luke	luke	PROPN
dpc-688	22	49	’s	’s	PART
dpc-688	22	50	private	private	ADJ
dpc-688	22	51	hospital	hospital	NOUN
dpc-688	22	52	,	,	PUNCT
dpc-688	22	53	thessaloniki	thessaloniki	PROPN
dpc-688	22	54	,	,	PUNCT
dpc-688	22	55	greece	greece	PROPN
dpc-688	22	56	key	key	ADJ
dpc-688	22	57	words	word	NOUN
dpc-688	22	58	:	:	PUNCT
dpc-688	22	59	psoriasis	psoriasis	NOUN
dpc-688	22	60	,	,	PUNCT
dpc-688	22	61	adenocarcinoma	adenocarcinoma	NOUN
dpc-688	22	62	,	,	PUNCT
dpc-688	22	63	apremilast	apremilast	ADJ
dpc-688	22	64	,	,	PUNCT
dpc-688	22	65	phosphodiesterase	phosphodiesterase	NOUN
dpc-688	22	66	inhibitor	inhibitor	NOUN
dpc-688	22	67	,	,	PUNCT
dpc-688	22	68	treatment	treatment	NOUN
dpc-688	22	69	citation	citation	NOUN
dpc-688	22	70	:	:	PUNCT
dpc-688	22	71	apalla	apalla	PROPN
dpc-688	22	72	z	z	PROPN
dpc-688	22	73	,	,	PUNCT
dpc-688	22	74	psarakis	psarakis	PROPN
dpc-688	22	75	e	e	PROPN
dpc-688	22	76	,	,	PUNCT
dpc-688	22	77	lallas	lallas	PROPN
dpc-688	22	78	a	a	PRON
dpc-688	22	79	,	,	PUNCT
dpc-688	22	80	koukouthaki	koukouthaki	PROPN
dpc-688	22	81	a	a	X
dpc-688	22	82	,	,	PUNCT
dpc-688	22	83	fassas	fassa	NOUN
dpc-688	22	84	a	a	PRON
dpc-688	22	85	,	,	PUNCT
dpc-688	22	86	smaragdi	smaragdi	NOUN
dpc-688	22	87	m.	m.	NOUN
dpc-688	22	88	psoriasis	psoriasis	NOUN
dpc-688	22	89	in	in	ADP
dpc-688	22	90	patients	patient	NOUN
dpc-688	22	91	with	with	ADP
dpc-688	22	92	active	active	ADJ
dpc-688	22	93	lung	lung	NOUN
dpc-688	22	94	cancer	cancer	NOUN
dpc-688	22	95	:	:	PUNCT
dpc-688	22	96	is	be	AUX
dpc-688	22	97	apremilast	apremilast	VERB
dpc-688	22	98	a	a	DET
dpc-688	22	99	safe	safe	ADJ
dpc-688	22	100	option	option	NOUN
dpc-688	22	101	?	?	PUNCT
dpc-688	23	1	dermatol	dermatol	NOUN
dpc-688	23	2	pract	pract	PROPN
dpc-688	23	3	concept	concept	NOUN
dpc-688	23	4	.	.	PUNCT
dpc-688	24	1	2019;9(4):300	2019;9(4):300	NUM
dpc-688	24	2	-	-	NUM
dpc-688	24	3	301	301	NUM
dpc-688	24	4	.	.	PUNCT
dpc-688	24	5	doi	doi	PROPN
dpc-688	24	6	:	:	PUNCT
dpc-688	24	7	https://doi.org/10.5826/dpc.0904a11	https://doi.org/10.5826/dpc.0904a11	PROPN
dpc-688	24	8	accepted	accept	VERB
dpc-688	24	9	:	:	PUNCT
dpc-688	24	10	may	may	AUX
dpc-688	24	11	22	22	NUM
dpc-688	24	12	,	,	PUNCT
dpc-688	24	13	2019	2019	NUM
dpc-688	24	14	;	;	PUNCT
dpc-688	24	15	published	publish	VERB
dpc-688	24	16	:	:	PUNCT
dpc-688	24	17	october	october	PROPN
dpc-688	24	18	31	31	NUM
dpc-688	24	19	,	,	PUNCT
dpc-688	24	20	2019	2019	NUM
dpc-688	24	21	copyright	copyright	NOUN
dpc-688	24	22	:	:	PUNCT
dpc-688	25	1	©	©	PROPN
dpc-688	25	2	2019	2019	NUM
dpc-688	25	3	apalla	apalla	PROPN
dpc-688	25	4	et	et	PROPN
dpc-688	25	5	 	 	SPACE
dpc-688	25	6	al	al	PROPN
dpc-688	25	7	.	.	PUNCT
dpc-688	26	1	this	this	PRON
dpc-688	26	2	is	be	AUX
dpc-688	26	3	an	an	DET
dpc-688	26	4	open	open	ADJ
dpc-688	26	5	-	-	PUNCT
dpc-688	26	6	access	access	NOUN
dpc-688	26	7	article	article	NOUN
dpc-688	26	8	distributed	distribute	VERB
dpc-688	26	9	under	under	ADP
dpc-688	26	10	the	the	DET
dpc-688	26	11	terms	term	NOUN
dpc-688	26	12	of	of	ADP
dpc-688	26	13	the	the	DET
dpc-688	26	14	creative	creative	ADJ
dpc-688	26	15	commons	common	NOUN
dpc-688	26	16	attribution	attribution	NOUN
dpc-688	26	17	license	license	NOUN
dpc-688	26	18	,	,	PUNCT
dpc-688	26	19	which	which	PRON
dpc-688	26	20	permits	permit	VERB
dpc-688	26	21	unrestricted	unrestricted	ADJ
dpc-688	26	22	use	use	NOUN
dpc-688	26	23	,	,	PUNCT
dpc-688	26	24	distribution	distribution	NOUN
dpc-688	26	25	,	,	PUNCT
dpc-688	26	26	and	and	CCONJ
dpc-688	26	27	reproduction	reproduction	NOUN
dpc-688	26	28	in	in	ADP
dpc-688	26	29	any	any	DET
dpc-688	26	30	medium	medium	NOUN
dpc-688	26	31	,	,	PUNCT
dpc-688	26	32	provided	provide	VERB
dpc-688	26	33	the	the	DET
dpc-688	26	34	original	original	ADJ
dpc-688	26	35	author	author	NOUN
dpc-688	26	36	and	and	CCONJ
dpc-688	26	37	source	source	NOUN
dpc-688	26	38	are	be	AUX
dpc-688	26	39	credited	credit	VERB
dpc-688	26	40	.	.	PUNCT
dpc-688	27	1	funding	funding	NOUN
dpc-688	27	2	:	:	PUNCT
dpc-688	27	3	none	none	NOUN
dpc-688	27	4	.	.	PUNCT
dpc-688	28	1	competing	compete	VERB
dpc-688	28	2	interests	interest	NOUN
dpc-688	28	3	:	:	PUNCT
dpc-688	28	4	the	the	DET
dpc-688	28	5	authors	author	NOUN
dpc-688	28	6	have	have	VERB
dpc-688	28	7	no	no	DET
dpc-688	28	8	conflicts	conflict	NOUN
dpc-688	28	9	of	of	ADP
dpc-688	28	10	interest	interest	NOUN
dpc-688	28	11	to	to	PART
dpc-688	28	12	disclose	disclose	VERB
dpc-688	28	13	.	.	PUNCT
dpc-688	29	1	authorship	authorship	NOUN
dpc-688	29	2	:	:	PUNCT
dpc-688	29	3	all	all	DET
dpc-688	29	4	authors	author	NOUN
dpc-688	29	5	have	have	AUX
dpc-688	29	6	contributed	contribute	VERB
dpc-688	29	7	significantly	significantly	ADV
dpc-688	29	8	to	to	ADP
dpc-688	29	9	this	this	DET
dpc-688	29	10	publication	publication	NOUN
dpc-688	29	11	.	.	PUNCT
dpc-688	30	1	corresponding	correspond	VERB
dpc-688	30	2	author	author	NOUN
dpc-688	30	3	:	:	PUNCT
dpc-688	30	4	zoe	zoe	NOUN
dpc-688	30	5	apalla	apalla	PROPN
dpc-688	30	6	,	,	PUNCT
dpc-688	30	7	md	md	PROPN
dpc-688	30	8	,	,	PUNCT
dpc-688	30	9	phd	phd	PROPN
dpc-688	30	10	,	,	PUNCT
dpc-688	30	11	124	124	NUM
dpc-688	30	12	delfon	delfon	NOUN
dpc-688	30	13	str	str	VERB
dpc-688	30	14	,	,	PUNCT
dpc-688	30	15	pc	pc	NOUN
dpc-688	30	16	54643	54643	NUM
dpc-688	30	17	,	,	PUNCT
dpc-688	30	18	thessaloniki	thessaloniki	PROPN
dpc-688	30	19	,	,	PUNCT
dpc-688	30	20	greece	greece	PROPN
dpc-688	30	21	.	.	PUNCT
dpc-688	31	1	email	email	NOUN
dpc-688	31	2	:	:	PUNCT
dpc-688	31	3	zoimd@yahoo.gr	zoimd@yahoo.gr	NOUN
dpc-688	31	4	letter	letter	NOUN
dpc-688	31	5	|	|	ADV
dpc-688	31	6	dermatol	dermatol	ADJ
dpc-688	31	7	pract	pract	NOUN
dpc-688	31	8	concept	concept	NOUN
dpc-688	31	9	2019;9(4):11	2019;9(4):11	NUM
dpc-688	31	10	301	301	NUM
dpc-688	31	11	harmless	harmless	ADJ
dpc-688	31	12	when	when	SCONJ
dpc-688	31	13	given	give	VERB
dpc-688	31	14	in	in	ADP
dpc-688	31	15	patients	patient	NOUN
dpc-688	31	16	with	with	ADP
dpc-688	31	17	psoriasis	psoriasis	NOUN
dpc-688	31	18	and	and	CCONJ
dpc-688	31	19	concomitant	concomitant	ADJ
dpc-688	31	20	lung	lung	NOUN
dpc-688	31	21	adenocarcinoma	adenocarcinoma	NOUN
dpc-688	31	22	.	.	PUNCT
dpc-688	32	1	conclusions	conclusion	NOUN
dpc-688	32	2	we	we	PRON
dpc-688	32	3	report	report	VERB
dpc-688	32	4	a	a	DET
dpc-688	32	5	favorable	favorable	ADJ
dpc-688	32	6	response	response	NOUN
dpc-688	32	7	of	of	ADP
dpc-688	32	8	psoriatic	psoriatic	ADJ
dpc-688	32	9	lesions	lesion	NOUN
dpc-688	32	10	to	to	PART
dpc-688	32	11	apremilast	apremilast	VERB
dpc-688	32	12	in	in	ADP
dpc-688	32	13	a	a	DET
dpc-688	32	14	patient	patient	NOUN
dpc-688	32	15	suffering	suffering	NOUN
dpc-688	32	16	from	from	ADP
dpc-688	32	17	metastatic	metastatic	ADJ
dpc-688	32	18	lung	lung	NOUN
dpc-688	32	19	adenocarcinoma	adenocarcinoma	NOUN
dpc-688	32	20	,	,	PUNCT
dpc-688	32	21	without	without	ADP
dpc-688	32	22	any	any	DET
dpc-688	32	23	adverse	adverse	ADJ
dpc-688	32	24	event	event	NOUN
dpc-688	32	25	.	.	PUNCT
dpc-688	33	1	definite	definite	ADJ
dpc-688	33	2	conclusions	conclusion	NOUN
dpc-688	33	3	can	can	AUX
dpc-688	33	4	not	not	PART
dpc-688	33	5	be	be	AUX
dpc-688	33	6	extracted	extract	VERB
dpc-688	33	7	before	before	SCONJ
dpc-688	33	8	further	further	ADJ
dpc-688	33	9	studies	study	NOUN
dpc-688	33	10	confirm	confirm	VERB
dpc-688	33	11	the	the	DET
dpc-688	33	12	safety	safety	NOUN
dpc-688	33	13	of	of	ADP
dpc-688	33	14	apremilast	apremilast	NOUN
dpc-688	33	15	in	in	ADP
dpc-688	33	16	a	a	DET
dpc-688	33	17	larger	large	ADJ
dpc-688	33	18	number	number	NOUN
dpc-688	33	19	of	of	ADP
dpc-688	33	20	patients	patient	NOUN
dpc-688	33	21	with	with	ADP
dpc-688	33	22	concurrent	concurrent	ADJ
dpc-688	33	23	malignancies	malignancy	NOUN
dpc-688	33	24	.	.	PUNCT
dpc-688	34	1	references	reference	NOUN
dpc-688	34	2	1	1	NUM
dpc-688	34	3	.	.	PUNCT
dpc-688	35	1	paul	paul	PROPN
dpc-688	35	2	c	c	PROPN
dpc-688	35	3	,	,	PUNCT
dpc-688	35	4	cather	cather	PROPN
dpc-688	35	5	j	j	PROPN
dpc-688	35	6	,	,	PUNCT
dpc-688	35	7	gooderham	gooderham	PROPN
dpc-688	35	8	m	m	PROPN
dpc-688	35	9	,	,	PUNCT
dpc-688	35	10	et	et	PROPN
dpc-688	35	11	 	 	SPACE
dpc-688	35	12	al	al	PROPN
dpc-688	35	13	.	.	PROPN
dpc-688	35	14	 	 	SPACE
dpc-688	35	15	efficacy	efficacy	NOUN
dpc-688	35	16	and	and	CCONJ
dpc-688	35	17	safety	safety	NOUN
dpc-688	35	18	of	of	ADP
dpc-688	35	19	apremilast	apremilast	ADJ
dpc-688	35	20	,	,	PUNCT
dpc-688	35	21	an	an	DET
dpc-688	35	22	oral	oral	ADJ
dpc-688	35	23	phosphodiesterase	phosphodiesterase	NOUN
dpc-688	35	24	4	4	NUM
dpc-688	35	25	inhibitor	inhibitor	NOUN
dpc-688	35	26	,	,	PUNCT
dpc-688	35	27	in	in	ADP
dpc-688	35	28	patients	patient	NOUN
dpc-688	35	29	with	with	ADP
dpc-688	35	30	moderate	moderate	ADJ
dpc-688	35	31	-	-	PUNCT
dpc-688	35	32	to	to	ADP
dpc-688	35	33	-	-	PUNCT
dpc-688	35	34	severe	severe	ADJ
dpc-688	35	35	plaque	plaque	NOUN
dpc-688	35	36	psoriasis	psoriasis	NOUN
dpc-688	35	37	over	over	ADP
dpc-688	35	38	52	52	NUM
dpc-688	35	39	weeks	week	NOUN
dpc-688	35	40	:	:	PUNCT
dpc-688	35	41	a	a	DET
dpc-688	35	42	phase	phase	NOUN
dpc-688	35	43	iii	iii	NOUN
dpc-688	35	44	,	,	PUNCT
dpc-688	35	45	randomized	randomize	VERB
dpc-688	35	46	controlled	control	VERB
dpc-688	35	47	trial	trial	NOUN
dpc-688	35	48	(	(	PUNCT
dpc-688	35	49	esteem	esteem	NOUN
dpc-688	35	50	2	2	NUM
dpc-688	35	51	)	)	PUNCT
dpc-688	35	52	.	.	PUNCT
dpc-688	36	1	br	br	PROPN
dpc-688	36	2	j	j	PROPN
dpc-688	36	3	dermatol	dermatol	NOUN
dpc-688	36	4	.	.	PUNCT
dpc-688	36	5	 	 	SPACE
dpc-688	37	1	2015;173(6):1387	2015;173(6):1387	PROPN
dpc-688	37	2	-	-	SYM
dpc-688	37	3	1399	1399	NUM
dpc-688	37	4	.	.	PUNCT
dpc-688	38	1	2	2	X
dpc-688	38	2	.	.	X
dpc-688	38	3	pullamsetti	pullamsetti	PROPN
dpc-688	38	4	ss	ss	PROPN
dpc-688	38	5	,	,	PUNCT
dpc-688	38	6	banat	banat	PROPN
dpc-688	38	7	ga	ga	PROPN
dpc-688	38	8	,	,	PUNCT
dpc-688	38	9	schmall	schmall	NOUN
dpc-688	38	10	a	a	X
dpc-688	38	11	,	,	PUNCT
dpc-688	38	12	et	et	PROPN
dpc-688	38	13	 	 	SPACE
dpc-688	38	14	al	al	PROPN
dpc-688	38	15	.	.	PUNCT
dpc-688	39	1	phosphodiesterase-4	phosphodiesterase-4	NOUN
dpc-688	39	2	promotes	promote	VERB
dpc-688	39	3	proliferation	proliferation	NOUN
dpc-688	39	4	and	and	CCONJ
dpc-688	39	5	angiogenesis	angiogenesis	NOUN
dpc-688	39	6	of	of	ADP
dpc-688	39	7	lung	lung	NOUN
dpc-688	39	8	cancer	cancer	NOUN
dpc-688	39	9	by	by	ADP
dpc-688	39	10	crosstalk	crosstalk	NOUN
dpc-688	39	11	with	with	ADP
dpc-688	39	12	hif	hif	PROPN
dpc-688	39	13	.	.	PUNCT
dpc-688	39	14	oncogene	oncogene	NOUN
dpc-688	39	15	.	.	PUNCT
dpc-688	40	1	2013;32(9):1121	2013;32(9):1121	NUM
dpc-688	40	2	-	-	SYM
dpc-688	40	3	1134	1134	NUM
dpc-688	40	4	.	.	PUNCT
dpc-688	41	1	evidence	evidence	NOUN
dpc-688	41	2	on	on	ADP
dpc-688	41	3	the	the	DET
dpc-688	41	4	safety	safety	NOUN
dpc-688	41	5	of	of	ADP
dpc-688	41	6	small	small	ADJ
dpc-688	41	7	molecules	molecule	NOUN
dpc-688	41	8	in	in	ADP
dpc-688	41	9	the	the	DET
dpc-688	41	10	context	context	NOUN
dpc-688	41	11	of	of	ADP
dpc-688	41	12	psoriatic	psoriatic	ADJ
dpc-688	41	13	patients	patient	NOUN
dpc-688	41	14	with	with	ADP
dpc-688	41	15	known	know	VERB
dpc-688	41	16	concomitant	concomitant	ADJ
dpc-688	41	17	malignancies	malignancy	NOUN
dpc-688	41	18	is	be	AUX
dpc-688	41	19	poor	poor	ADJ
dpc-688	41	20	.	.	PUNCT
dpc-688	42	1	apremilast	apremilast	PROPN
dpc-688	42	2	is	be	AUX
dpc-688	42	3	considered	consider	VERB
dpc-688	42	4	one	one	NUM
dpc-688	42	5	of	of	ADP
dpc-688	42	6	the	the	DET
dpc-688	42	7	safest	safe	ADJ
dpc-688	42	8	options	option	NOUN
dpc-688	42	9	for	for	ADP
dpc-688	42	10	the	the	DET
dpc-688	42	11	treatment	treatment	NOUN
dpc-688	42	12	of	of	ADP
dpc-688	42	13	psoriasis	psoriasis	NOUN
dpc-688	42	14	.	.	PUNCT
dpc-688	43	1	however	however	ADV
dpc-688	43	2	,	,	PUNCT
dpc-688	43	3	exclusion	exclusion	NOUN
dpc-688	43	4	of	of	ADP
dpc-688	43	5	patients	patient	NOUN
dpc-688	43	6	with	with	ADP
dpc-688	43	7	known	known	ADJ
dpc-688	43	8	malignancies	malignancy	NOUN
dpc-688	43	9	from	from	ADP
dpc-688	43	10	clinical	clinical	ADJ
dpc-688	43	11	trials	trial	NOUN
dpc-688	43	12	does	do	AUX
dpc-688	43	13	not	not	PART
dpc-688	43	14	allow	allow	VERB
dpc-688	43	15	safe	safe	ADJ
dpc-688	43	16	conclusions	conclusion	NOUN
dpc-688	43	17	for	for	ADP
dpc-688	43	18	patients	patient	NOUN
dpc-688	43	19	with	with	ADP
dpc-688	43	20	solid	solid	ADJ
dpc-688	43	21	organ	organ	NOUN
dpc-688	43	22	malignancies	malignancy	NOUN
dpc-688	43	23	.	.	PUNCT
dpc-688	44	1	we	we	PRON
dpc-688	44	2	decided	decide	VERB
dpc-688	44	3	to	to	PART
dpc-688	44	4	use	use	VERB
dpc-688	44	5	apremilast	apremilast	NOUN
dpc-688	44	6	based	base	VERB
dpc-688	44	7	on	on	ADP
dpc-688	44	8	the	the	DET
dpc-688	44	9	lack	lack	NOUN
dpc-688	44	10	of	of	ADP
dpc-688	44	11	contraindication	contraindication	NOUN
dpc-688	44	12	,	,	PUNCT
dpc-688	44	13	as	as	ADP
dpc-688	44	14	per	per	ADP
dpc-688	44	15	summary	summary	NOUN
dpc-688	44	16	of	of	ADP
dpc-688	44	17	product	product	NOUN
dpc-688	44	18	characteristics	characteristic	NOUN
dpc-688	44	19	.	.	PUNCT
dpc-688	45	1	furthermore	furthermore	ADV
dpc-688	45	2	,	,	PUNCT
dpc-688	45	3	we	we	PRON
dpc-688	45	4	were	be	AUX
dpc-688	45	5	encouraged	encourage	VERB
dpc-688	45	6	to	to	PART
dpc-688	45	7	follow	follow	VERB
dpc-688	45	8	this	this	DET
dpc-688	45	9	decision	decision	NOUN
dpc-688	45	10	based	base	VERB
dpc-688	45	11	on	on	ADP
dpc-688	45	12	data	datum	NOUN
dpc-688	45	13	about	about	ADP
dpc-688	45	14	the	the	DET
dpc-688	45	15	pathophysiological	pathophysiological	ADJ
dpc-688	45	16	role	role	NOUN
dpc-688	45	17	of	of	ADP
dpc-688	45	18	phosphodiesterase	phosphodiesterase	NOUN
dpc-688	45	19	4	4	NUM
dpc-688	45	20	(	(	PUNCT
dpc-688	45	21	pde4	pde4	NOUN
dpc-688	45	22	)	)	PUNCT
dpc-688	45	23	in	in	ADP
dpc-688	45	24	lung	lung	NOUN
dpc-688	45	25	and	and	CCONJ
dpc-688	45	26	other	other	ADJ
dpc-688	45	27	cancer	cancer	NOUN
dpc-688	45	28	,	,	PUNCT
dpc-688	45	29	at	at	ADP
dpc-688	45	30	a	a	DET
dpc-688	45	31	cellular	cellular	ADJ
dpc-688	45	32	level	level	NOUN
dpc-688	45	33	.	.	PUNCT
dpc-688	46	1	analytically	analytically	ADV
dpc-688	46	2	,	,	PUNCT
dpc-688	46	3	in	in	ADP
dpc-688	46	4	a	a	DET
dpc-688	46	5	previous	previous	ADJ
dpc-688	46	6	study	study	NOUN
dpc-688	46	7	,	,	PUNCT
dpc-688	46	8	investigators	investigator	NOUN
dpc-688	46	9	exposed	expose	VERB
dpc-688	46	10	different	different	ADJ
dpc-688	46	11	lung	lung	NOUN
dpc-688	46	12	cancer	cancer	NOUN
dpc-688	46	13	cell	cell	NOUN
dpc-688	46	14	lines	line	NOUN
dpc-688	46	15	to	to	PART
dpc-688	46	16	hypoxia	hypoxia	VERB
dpc-688	46	17	and	and	CCONJ
dpc-688	46	18	measured	measure	VERB
dpc-688	46	19	the	the	DET
dpc-688	46	20	activity	activity	NOUN
dpc-688	46	21	and	and	CCONJ
dpc-688	46	22	expression	expression	NOUN
dpc-688	46	23	of	of	ADP
dpc-688	46	24	pde4	pde4	NOUN
dpc-688	46	25	.	.	PUNCT
dpc-688	47	1	interestingly	interestingly	ADV
dpc-688	47	2	,	,	PUNCT
dpc-688	47	3	they	they	PRON
dpc-688	47	4	found	find	VERB
dpc-688	47	5	that	that	SCONJ
dpc-688	47	6	pde4	pde4	NOUN
dpc-688	47	7	is	be	AUX
dpc-688	47	8	expressed	express	VERB
dpc-688	47	9	in	in	ADP
dpc-688	47	10	lung	lung	NOUN
dpc-688	47	11	cancer	cancer	NOUN
dpc-688	47	12	cells	cell	NOUN
dpc-688	47	13	,	,	PUNCT
dpc-688	47	14	cross	cros	NOUN
dpc-688	47	15	-	-	NOUN
dpc-688	47	16	talks	talk	NOUN
dpc-688	47	17	with	with	ADP
dpc-688	47	18	hypoxia	hypoxia	NOUN
dpc-688	47	19	-	-	PUNCT
dpc-688	47	20	inducible	inducible	ADJ
dpc-688	47	21	factor	factor	NOUN
dpc-688	47	22	signaling	signal	VERB
dpc-688	47	23	,	,	PUNCT
dpc-688	47	24	and	and	CCONJ
dpc-688	47	25	promotes	promote	VERB
dpc-688	47	26	lung	lung	NOUN
dpc-688	47	27	cancer	cancer	NOUN
dpc-688	47	28	progression	progression	NOUN
dpc-688	47	29	.	.	PUNCT
dpc-688	48	1	based	base	VERB
dpc-688	48	2	on	on	ADP
dpc-688	48	3	this	this	DET
dpc-688	48	4	observation	observation	NOUN
dpc-688	48	5	,	,	PUNCT
dpc-688	48	6	they	they	PRON
dpc-688	48	7	suggested	suggest	VERB
dpc-688	48	8	that	that	SCONJ
dpc-688	48	9	it	it	PRON
dpc-688	48	10	could	could	AUX
dpc-688	48	11	represent	represent	VERB
dpc-688	48	12	a	a	DET
dpc-688	48	13	potential	potential	ADJ
dpc-688	48	14	therapeutic	therapeutic	ADJ
dpc-688	48	15	target	target	NOUN
dpc-688	49	1	[	[	X
dpc-688	49	2	2	2	NUM
dpc-688	49	3	]	]	PUNCT
dpc-688	49	4	.	.	PUNCT
dpc-688	50	1	whether	whether	SCONJ
dpc-688	50	2	a	a	DET
dpc-688	50	3	similar	similar	ADJ
dpc-688	50	4	effect	effect	NOUN
dpc-688	50	5	would	would	AUX
dpc-688	50	6	occur	occur	VERB
dpc-688	50	7	in	in	ADP
dpc-688	50	8	vivo	vivo	NOUN
dpc-688	50	9	remains	remain	VERB
dpc-688	50	10	to	to	PART
dpc-688	50	11	be	be	AUX
dpc-688	50	12	investigated	investigate	VERB
dpc-688	50	13	further	far	ADV
dpc-688	50	14	.	.	PUNCT
dpc-688	51	1	however	however	ADV
dpc-688	51	2	,	,	PUNCT
dpc-688	51	3	the	the	DET
dpc-688	51	4	reported	report	VERB
dpc-688	51	5	effect	effect	NOUN
dpc-688	51	6	on	on	ADP
dpc-688	51	7	cell	cell	NOUN
dpc-688	51	8	lines	line	NOUN
dpc-688	51	9	indicates	indicate	VERB
dpc-688	51	10	that	that	SCONJ
dpc-688	51	11	pde4	pde4	NOUN
dpc-688	51	12	inhibition	inhibition	NOUN
dpc-688	51	13	is	be	AUX
dpc-688	51	14	quite	quite	ADV
dpc-688	51	15	likely	likely	ADJ
dpc-688	51	16	—	—	PUNCT
dpc-688	51	17	at	at	ADP
dpc-688	51	18	the	the	DET
dpc-688	51	19	very	very	ADV
dpc-688	51	20	least	least	ADJ
dpc-688	51	21	—	—	PUNCT
dpc-688	51	22	to	to	PART
dpc-688	51	23	be	be	AUX
dpc-688	51	24	figure	figure	NOUN
dpc-688	51	25	1	1	NUM
dpc-688	51	26	.	.	PUNCT
dpc-688	51	27	erythematous	erythematous	ADJ
dpc-688	51	28	,	,	PUNCT
dpc-688	51	29	scaly	scaly	NOUN
dpc-688	51	30	plaques	plaque	NOUN
dpc-688	51	31	involving	involve	VERB
dpc-688	51	32	the	the	DET
dpc-688	51	33	lower	low	ADJ
dpc-688	51	34	back	back	NOUN
dpc-688	51	35	(	(	PUNCT
dpc-688	51	36	a	a	NOUN
dpc-688	51	37	)	)	PUNCT
dpc-688	51	38	and	and	CCONJ
dpc-688	51	39	both	both	DET
dpc-688	51	40	legs	leg	NOUN
dpc-688	51	41	(	(	PUNCT
dpc-688	51	42	b	b	NOUN
dpc-688	51	43	)	)	PUNCT
dpc-688	51	44	.	.	PUNCT
dpc-688	52	1	complete	complete	ADJ
dpc-688	52	2	clearance	clearance	NOUN
dpc-688	52	3	16	16	NUM
dpc-688	52	4	weeks	week	NOUN
dpc-688	52	5	after	after	ADP
dpc-688	52	6	apremilast	apremilast	NOUN
dpc-688	52	7	initiation	initiation	NOUN
dpc-688	52	8	(	(	PUNCT
dpc-688	52	9	c	c	X
dpc-688	52	10	,	,	PUNCT
dpc-688	52	11	d	d	NOUN
dpc-688	52	12	)	)	PUNCT
dpc-688	52	13	.	.	PUNCT
dpc-688	53	1	[	[	X
dpc-688	53	2	copyright	copyright	NOUN
dpc-688	53	3	:	:	PUNCT
dpc-688	53	4	©	©	PROPN
dpc-688	53	5	2019	2019	NUM
dpc-688	53	6	apalla	apalla	PROPN
dpc-688	53	7	et	et	PROPN
dpc-688	53	8	 	 	SPACE
dpc-688	53	9	al	al	PROPN
dpc-688	53	10	.	.	PROPN
dpc-688	53	11	]	]	PUNCT